BioCentury
ARTICLE | Clinical News

Xtoll Chaperonin 10: Phase IIa data

August 28, 2006 7:00 AM UTC

Data from a double-blind Phase IIa trial in 23 patients showed that the primary endpoint of DAS28 and ACR scores improved in all patients from day 14 and continued to improve at day 84. Three patients...